Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00932451
Other study ID # A8081005
Secondary ID 2009-012504-13
Status Completed
Phase Phase 2
First received June 30, 2009
Last updated February 5, 2016
Start date January 2010
Est. completion date December 2015

Study information

Verified date February 2016
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This is a Phase 2 trial that will evaluate the safety and efficacy of PF-02341066 in patients with advanced non-small cell lung cancer with a specific gene profile involving the ALK gene. This trial will also allow patients from a Phase 3 trial who received standard of care chemotherapy (Study A8081007) to receive PF-02341066.


Recruitment information / eligibility

Status Completed
Enrollment 1069
Est. completion date December 2015
Est. primary completion date March 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- histologically or cytologically proven diagnosis of non-small cell lung cancer

- positive for the ALK fusion gene (test provided by either a central laboratory. Local laboratory may be used for certain cases)

- may have received pemetrexed or docetaxel from previous Phase 3 trial (A8081007) and discontinued treatment due to Response Evaluation Criterion in Solid Tumors (RECIST)-defined progression. or, once the primary endpoint of Study A8081007 has been analyzed and the results made available, at any time without RECIST-defined progression.

- Tumors can be measurable or non measurable

Exclusion Criteria:

- prior treatment with PF-02341066

- received no prior systemic treatment, chemotherapy or EGFR tyrosine kinase inhibitor, for advanced non-small cell lung cancer

- current enrollment in another therapeutic clinical trial

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
PF-02341066
PF-02341066, 250 mg BID, will be administered orally on a continuous schedule

Locations

Country Name City State
Australia Royal Adelaide Hospital, Department of Medical Oncology Adelaide South Australia
Australia Chris O'Brien Lifehouse Camperdown New South Wales
Australia Peter MacCallum Cancer Centre, Division of Haematology and Medical Oncology East Melbourne Victoria
Australia Department of Medical Oncology Nedlands Western Australia
Brazil Fundacao Pio XII Hospital de Cancer de Barretos Barretos SP
Brazil Associacao Hospital de Caridade de Ijui Ijui RS
Brazil Fundacao Hospital Amaral Carvalho Jau Sao Paulo
Brazil Hospital Sao Lucas da PUCRS Porto Alegre RS
Brazil Irmandade da Santa Casa de Misericordia de Porto Alegre Porto Alegre RS
Brazil Instituto Nacional do Câncer - INCA Rio de Janeiro RJ
Brazil Nucleo de Oncologia da Bahia Salvador BA
Brazil Fundacao Antonio Prudente Sao Paulo SP
Brazil Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira - ICESP Sao Paulo SP
Bulgaria MBAL Voennomeditsinska Academia, MMA HAT Sofia Sofia
Bulgaria Spetsializirana Bolnitsa za Aktivno Lechenie po Onkologiya, Klinika po himioterapiya Sofia
Bulgaria UMHAT Tsaritsa Yoanna - ISUL Sofia
Bulgaria MDOZS "Dr. Marko Markov", Otdelenie po onkoterapiya i paliativni grizhi Varna
Canada Alberta Health Services, Holy Cross Site Calgary Alberta
Canada Office of Dr. John McWhae Calgary Alberta
Canada Tom Baker Cancer Centre Calgary Alberta
Canada Cross Cancer Institute Edmonton Alberta
Canada Dr. Georges-L. Dumont Regional Hospital Moncton New Brunswick
Canada Dr. Leon Richard Oncology Centre Moncton New Brunswick
Canada Hopital Notre-Dame du Centre Hospitalier de l'Universite de Montreal (CHUM) Montreal Quebec
Canada Jewish General Hospsital Montreal Quebec
Canada Montreal General Hospital Montreal Quebec
Canada Royal Victoria Hospital Montreal Quebec
Canada St. Mary's Hospital Center Montreal Quebec
Canada Dr. Dana Blakolmer and Associates Oshawa Ontario
Canada RSM Durham Regional Cancer Centre - Lakeridge Health Oshawa Oshawa Ontario
Canada The Ottawa Hospital Cancer Center Ottawa Ontario
China 307 Hospital of PLA Beijing
China Cancer Institute and Hospital Chinese Academy of Medical Sciences and PUMC, Internal 4 Department Beijing
China Guangdong General Hospital Guangzhou
China SUN Yat-Sen University Cancer Center Guangzhou Guangdong
China Nanjing Bayi Hospital Nanjing Jiangsu
China Shanghai Chest Hospital Shanghai
China Shanghai Chest Hospital/Department of Pulmonary Medicine Shanghai
China Shanghai Pulmonary Hospital Shanghai
China Zhongshan Hospital Fudan University / Respiratory Department Shanghai
France Centre Francois Baclesse Caen Cedex 05
France Centre Georges-François Leclerc Dijon
France Hopital Albert Michallon Grenoble Cedex 09
France APHM - Hopital Nord / Service d'Oncologie Multidisciplinaire et Innovations Thérapeutiques Marseille Cedex 20
France Centre Antoine Lacassagne NICE Cedex 2
France Hospital Cochin Paris
France Hopital Tenon Paris cedex 20
France Centre Rene Gauducheau / Service d'Oncologie Medicale St Herblain Cedex
France Institut Gustave Roussy Villejuif
Germany Universitaetsklinik Carl-Gustav-Carus Dresden Dresden
Germany Westdeutsches Tumorzentrum, Universitaetsklinikum Essen, Innere Klinik - Tumorforschung Essen
Germany Krankenhaus Grosshansdorf, Zentrum fuer Pneumologie und Thoraxchirurgie Grosshansdorf
Germany Ambulantes Krebszentrum Hamburg Hamburg
Germany Thoraxklinik am Universitaetsklinikum Heidelberg, Internistische Onkologie der Thoraxtumoren Heidelberg
Germany St. Vincentius-Kliniken Karlsruhe Karlsruhe
Germany Klinikum der Universitaet zu Koeln, Klinik I fuer Innere Medizin Koeln
Germany Klinikum der Universitaet Muenchen, Medizinische Klink - Innenstadt, Pneumologie Muenchen
Germany Pius-Hospital Oldenburg Oldenburg
Germany HSK Dr.- Horst-Schmidt-Kliniken GmbH, Haematologie/Onkologie, Innere Medizin III Wiesbaden
Greece General Hospital of Chest Diseases of Athens "Sotiria" Athens
Greece General Hospital of Thessaloniki Georgios Papanikolaou, Lung Cancer Neoplasia Research Department Exohi Thessaloniki
Greece University General Hospital of Heraklion/ Department of Clinical Oncology Heraklion Crete
Hong Kong Division of Respiratory and Critical Care Medicine, Department of Medicine, Queen Mary Hospital Pokfulam
Hong Kong Department of Clinical Oncology, Prince of Wales Hospital Shatin, New Territories
Hong Kong Tuen Mun Hospital, Department of Clinical Oncology Tuen Mun, New Territories
Hungary Orszagos Koranyi TBC es Pulmonologiai Intezet, VI. Bronchologia Budapest
Hungary Semmelweis Egyetem Pulmonologia Intezet Budapest
Hungary Debreceni Egyetem Orvos - es Egeszsegtudomanyi Centrum, Tudogyogyaszati Klinika Debrecen
Hungary Veszprem Megyei Onkormanyzat Tudogyogyintezete Farkasgyepu
Hungary Fejer Megyei Szent Gyorgy Korhaz, Pulmonologiai Osztaly Szekesfehervar
Hungary Pest Megyei Tudogyogyintezet, III. Osztaly Torokbalint
Ireland Department of Medical Oncology Dublin 8
Ireland Department of Medical Oncology Galway
Italy Divisione di Oncologia Medica, Ospedale San Giuseppe Moscati, Citta' Ospedaliera Avellino
Italy S.C. Oncologia Medica Firenze
Italy Oncologia Medica A Genova
Italy Ospedale Versilia, Oncologia Medica Lido di Camaiore (LU)
Italy Ospedale San Luca Lucca
Italy Dipartimento Oncologia Medica, UO Medicina 1Q A, Unita' Nuovi Farmaci e Terapie Innovative Milano
Italy Istituto Europeo di Oncologia Milano
Italy Ospedale Niguarda Ca' Granda Dipartimento Oncologico, SC Divisione di Oncologia Medica Falk Milano
Italy Nuovo Ospedale San Gerardo Monza
Italy Azienda Ospedaliera Universitaria San Luigi Gonzaga Orbassano (TO)
Italy SC Oncologia Medica, Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia Perugia
Italy Unita' Operativa Complessa di Pneumologia Oncologica I, Padiglione Flaiani Roma
Italy Centro C.O.E.S., A.O. San Giovanni Battista Le Molinette Torino
Japan Hyogo Cancer Center Akashi Hyogo
Japan National Cancer Center Hospital Chuo-ku Tokyo
Japan National Kyushu Cancer Center/Department of Thoracic Oncology Fukuoka
Japan National Cancer Center Hospital East Kashiwa Chiba
Japan Aichi cancer center central hospital Nagoya Aichi
Japan Okayama University Hospital / Department of Respiratory Medicine and Allergy Okayama
Japan Kinki University Hospital Osakasayama-shi Osaka
Japan National Hospital Organization Hokkaido Cancer Center Sapporo Hokkaido
Japan Shizuoka Cancer Center Sunto-gun Shizuoka
Japan The Cancer Institute Hospital of JFCR Tokyo
Korea, Republic of National Cancer Center, Center for Lung Cancer Gyeonggi-do
Korea, Republic of Samsung Medical Center, Sungkyunkwan Univ School of Medicine Seoul
Korea, Republic of Seoul National University Hospital / Department of Internal Medicine Seoul
Netherlands Universitair Medisch Centrum Groningen / Afdeling Inwendige Geneeskunde Groningen
Poland Klinika Onkologii i Radioterapii Gdansk
Poland Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc Olsztyn
Poland Oddzial Onkologii Klinicznej z Pododdzialem Dziennej Chemioterapii Poznan
Poland Zaklad Diagnostyki Obrazowej Poznan
Russian Federation Republican Clinical Oncology Dispensary of the Ministry of Health of Tatarstan Republic Kazan
Russian Federation State Institution "National Cancer Research Center named after N.N. Blokhin' RAMS" Moscow
Russian Federation City Clinical Oncology Dispensary Saint-Petersburg
Russian Federation Research Institute of Pulmonology Saint-Petersburg
Russian Federation Saint-Petersburg State Medical University named after I.P.Pavlov of Roszdrav Saint-Petersburg
Russian Federation City Clinical Oncology Dispensary St. Petersburg
Spain Complexo Hospitalario Universitario A Coruña. Hospital Teresa Herrera (Materno-Infantil) A Coruña
Spain Hospital Universitari Germans Trias I Pujol Badalona Barcelona
Spain Hospital Del Mar Barcelona
Spain Hospital General Universitari Vall D´Hebron Barcelona
Spain Institut Catala Doncologia - Hospital Duran I Reynals L'hospitalet de Llobregat Barcelona
Spain Hospital Universitario La Paz Madrid
Spain Hospital Universitario Central de Asturias Oviedo Asturias
Spain Hospital de Navarra Pamplona
Spain Consorcio Hospitalario Parc Tauli Sabadell Barcelona
Spain Hospital Universitario Marques de Valdecilla Santander
Spain Hospital Universitario Virgen Del Rocio Sevilla
Sweden Karolinska Universitetssjukhuset, Onkologiska kliniken Stockholm
Taiwan National Cheng Kung University Hospital Tainan
Taiwan National Taiwan University Hospital, Department of Internal Medicine Taipei
Taiwan Taipei Veterans General Hospital, Chest Department Taipei
United Kingdom Nuffield Health Wessex Hospital Eastleigh
United Kingdom Cancer and Haematology Centre, Headington Oxford
United Kingdom Department of Oncology London
United Kingdom Kings College London at Guy's Hospital London
United Kingdom Royal Marsden Hospital London
United Kingdom Christie Hospital NHS Trust, Department of Medical Oncology Manchester
United Kingdom Somers Cancer Research Building, M824 Southampton
United Kingdom Royal Marsden Hospital Sutton Surrey
United States University of New Mexico Cancer Center Albuquerque New Mexico
United States University of New Mexico Eye Clinic Albuquerque New Mexico
United States Emory Clinic Atlanta Georgia
United States Emory University Clinic Atlanta Georgia
United States Emory University Hospital Atlanta Georgia
United States Emory University Hospital Midtown Atlanta Georgia
United States Georgia Cancer Specialists - Administrative Annex Atlanta Georgia
United States Winship Cancer Institution Atlanta Georgia
United States MCG Health Cancer Center Pharmacy Augusta Georgia
United States MCG Health System Pharmacy (Drug Shipment Only) Augusta Georgia
United States Medical College of Georgia Augusta Georgia
United States DRUG SHIPMENT: University of Colorado Cancer Center Aurora Colorado
United States Rocky Mountain Lions Eye Institute Aurora Colorado
United States University of Colorado Hospital Aurora Colorado
United States Comprehensive Blood and Cancer Center Bakersfield California
United States Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland
United States The Harry and Jeanette Cancer Research Building Baltimore Maryland
United States National Institutes of Health National Cancer Institute Bethesda Maryland
United States Tower Cancer Research Foundation Beverly Hills California
United States Tower Hematology Oncology Medical Group Beverly Hills California
United States University of Alabama at Birmingham Birmingham Alabama
United States University of Alabama at Birmingham Birmingham Alabama
United States Beth Isreal Deaconess Medical Center Boston Massachusetts
United States Beth Isreal Deaconess Medical Center, Pharmacy FD B18 Boston Massachusetts
United States Brigham and Women's Hospital Boston Massachusetts
United States Dana Farber Cancer Institute Boston Massachusetts
United States Dana Farber Cancer Institute/Pharmacy Boston Massachusetts
United States Massachusette General Hospital Boston Massachusetts
United States Massachussetts General Hospital Boston Massachusetts
United States All shipment of study drug should go to: Chapel Hill North Carolina
United States UNC Hospitals, The University of North Carolina at Chapel Hill Chapel Hill North Carolina
United States Medical University of South Carolina - Hollings Cancer Center Charleston South Carolina
United States Presbyterian Hospital Cancer Center Charlotte North Carolina
United States Rush University Medical Center Chicago Illinois
United States University of Chicago Medical Center Chicago Illinois
United States Cleveland Clinic Cleveland Ohio
United States James Care in Kenny Columbus Ohio
United States The Ohio State University Hospital East Columbus Ohio
United States The Ohio State University James Cancer Hospital and Solove Research Institute Columbus Ohio
United States Siteman Cancer Center- West County Creve Coeur Missouri
United States University of Texas Southwestern Medical Center at Dallas Dallas Texas
United States University of Texas Southwestern University Hospital - St. Paul Dallas Texas
United States University of Texas Southwestern University Hospital - Zale Lipshy Dallas Texas
United States Georgia Cancer Specialists-Stemmer Decatur Georgia
United States Kaiser Permanente Denver Colorado
United States Karmanos Cancer Institute Detroit Michigan
United States Tennessee Oncology, PLLC Dickson Tennessee
United States Pharma Resource East Providence Rhode Island
United States Vincent Armenio, MD East Providence Rhode Island
United States Karmanos Cancer lnstitute at Farmington Hllls Farmington Hills Michigan
United States Michael and Dianne Bienes Cancer Center, Holy Cross Hospital Fort Lauderdale Florida
United States Tennessee Oncology, PLLC Franklin Tennessee
United States Tennessee Oncology, PLLC Gallatin Tennessee
United States Ingalls Memorial Hospital Harvey Illinois
United States Ingalls Memorial Hospital (Drug Shipment Only) Harvey Illinois
United States Monroe Medical Associates Harvey Illinois
United States Tennessee Oncology, PLLC Hermitage Tennessee
United States Penn State Milton S. Hershey Medical Center, Penn State Hershey Cancer Institute Hershey Pennsylvania
United States Memorial Cancer Institute Hollywood Florida
United States Hawaii Medical Center East Honolulu Hawaii
United States OnCare Hawaii, Inc. Honolulu Hawaii
United States University of Hawaii - Cancer Research Center of Hawaii Honolulu Hawaii
United States The University of Texas Houston Texas
United States Presbyterian Hospital Huntersville Huntersville North Carolina
United States Southern Oncology Specialists Huntersville North Carolina
United States Indiana University Hospital Clarian Health Indianapolis Indiana
United States Indiana University Melvin and Bren Simon Cancer Center Indianapolis Indiana
United States Ship drug to: Investigational Drug Services Indianapolis Indiana
United States Wishard Memorial Hospital Indianapolis Indiana
United States Springmill Medical Clinic Indianopolis Indiana
United States Moores UCSD Cancer Center La Jolla California
United States UCSD Medical Center - La Jolla La Jolla California
United States Kaiser Permanente Lafayette Colorado
United States NSLIJ Health System/Monter Cancer Center Lake Success New York
United States Cancer Center of South Florida Foundation, Inc. Lake Worth Florida
United States Dartmouth Hitchcock Medical Center Lebanon New Hampshire
United States Tennessee Oncology, PLLC Lebanon Tennessee
United States University of Arkansas for Medical Research Little Rock Arkansas
United States Drug Shipping Address [IRB number 09-11-100]: Ronald Reagen University of California-Los Angeles Los Angeles California
United States Ronald Reagen University of California-Los Angeles Medical Center Los Angeles California
United States UCLA Opthalmic Oncology Center Los Angeles California
United States University of California-Los Angeles Los Angeles California
United States Georgia Cancer Specialists-Macon Macon Georgia
United States North Shore University Hospital Manhasset New York
United States Georgia Cancer Specialists-Kennestone Marietta Georgia
United States Presbyterian Hospital Matthews Matthews North Carolina
United States Monroe Medical Associates Munster Indiana
United States The Community Hospital Munster Indiana
United States Tennessee Oncology, PLLC Murfreesboro Tennessee
United States Sarah Cannon Research Institute (Administration) Nashville Tennessee
United States Sarah Cannon Research Institute (Pharmacy) Nashville Tennessee
United States Tennessee Oncology, PLLC Nashville Tennessee
United States Tennessee Oncology, PLLC Nashville Tennessee
United States Tennessee Oncology, PLLC Nashville Tennessee
United States Tennessee Oncology, PLLC Nashville Tennessee
United States The Vanderbilt Chemo Clinic Nashville Tennessee
United States Vanderbilt Cancer Clinic Nashville Tennessee
United States Clinical Trial Office New Haven Connecticut
United States Drug Shipping for Yale; C/O Thomas Ferenez, RPh, BCOP New Haven Connecticut
United States Smilow Cancer Hospital at Yale New Haven New Haven Connecticut
United States Yale Cancer Center New Haven Connecticut
United States Long Island Jewish Medical Center New Hyde Park New York
United States Columbia University Medical Center New York New York
United States Memorial Sloan - Kettering Cancer Center New York New York
United States Memorial Sloan-Kettering Cancer Center: Rockefeller Outpatient Pavillion New York New York
United States University of Nebraska Medical Center Omaha Nebraska
United States Department of Medicine MSG at SUNY HSC at Syracuse, INC., d/b/a University Physicians Oneida New York
United States Ship Drug To : Lorene Kong- University of California, Irvine-Pharmacy Orange California
United States University of California, Irvine-Medical Center Orange California
United States Department of Medicine MSG at SUNY HSC at Syracuse, INC., d/b/a University Physicians Oswego New York
United States Stanford University-Cancer Center Palo Alto California
United States Memorial Cancer Center (West) Pembroke Pines Florida
United States Abramson Cancer Center of the University of Pennsylvania Philadelphia Pennsylvania
United States Fox Chase Cancer Center Philadelphia Pennsylvania
United States Penn Presbyterian Medical Center Philadelphia Pennsylvania
United States University of Pittsburgh Medical Center Pittsburgh Pennsylvania
United States Oregon Health and Science University Portland Oregon
United States UC Davis Cancer Center Sacramento California
United States University of California Davis Medical Center Sacramento California
United States UCSD Medical Center - Hillcrest San Diego California
United States Georgia Cancer Specialists-Northside Sandy Springs Georgia
United States Santa Monica-UCLA Medical Center & Orthopaedic Hospital Clinical Laboratory Santa Monica California
United States UCLA Hematology Oncology-Santa Monica Santa Monica California
United States University of California-Los Angeles Santa Monica California
United States Redwood Regional Medical Group Inc Santa Rosa California
United States Lisa Nakatsu, RPh (Drug Shipment Address) Seattle Washington
United States Seattle Cancer Care Alliance Seattle Washington
United States Swedish Cancer Institute Seattle Washington
United States Swedish Medical Center Seattle Washington
United States University of Washington Medical Center Seattle Washington
United States Tennessee Oncology, PLLC Smyrna Tennessee
United States Barnes-Jewish Hospital St. Louis Missouri
United States Washington University School of Medicine St. Louis Missouri
United States Siteman Cancer Center St. Peters Missouri
United States Department of Medicine MSG at SUNY HSC at Syracuse, INC., d/b/a University Physicians Syracuse New York
United States SUNY Upstate Medical University, Regional Oncology Center Syracuse New York
United States H Lee Moffitt Cancer Center & Research Institute Tampa Florida
United States Monroe Medical Associates Tinley Park Illinois

Sponsors (1)

Lead Sponsor Collaborator
Pfizer

Countries where clinical trial is conducted

United States,  Australia,  Brazil,  Bulgaria,  Canada,  China,  France,  Germany,  Greece,  Hong Kong,  Hungary,  Ireland,  Italy,  Japan,  Korea, Republic of,  Netherlands,  Poland,  Russian Federation,  Spain,  Sweden,  Taiwan,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate 30 months No
Primary Type, incidence, severity, seriousness and relationship to study medication of adverse events and laboratory test abnormalities 30 months Yes
Secondary Duration of Response 30 months No
Secondary Disease Control Rate 30 months No
Secondary Overall Survival 30 months Yes
Secondary Patient reported symptoms of lung cancer and health-related quality of life 30 months Yes
Secondary Plasma concentrations of PF-02341066 30 months No
Secondary Types of EML4-ALK fusion variants and ALK gene expression 30 months No
Secondary Protein expression of identified biomarkers in serial tumor samples (when available) 30 months No
Secondary Progression Free Survival 30 months Yes
Secondary Time to Tumor Response 30 months No
Secondary QTc 30 months Yes
Secondary genotypes of alleles possibly associated with adverse hepatic or renal drug reactions 30 months Yes
See also
  Status Clinical Trial Phase
Completed NCT04879849 - A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers Phase 1
Completed NCT04426825 - A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Phase 2
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT02864394 - Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033) Phase 3
Completed NCT02810457 - Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer Phase 3
Recruiting NCT04592523 - A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
Recruiting NCT04838548 - A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer Phase 2
Recruiting NCT04077463 - A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer Phase 1
Recruiting NCT04603807 - A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases Phase 3
Recruiting NCT05167604 - Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
Completed NCT04948411 - Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil
Active, not recruiting NCT04487080 - A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Phase 3
Not yet recruiting NCT04255836 - Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC) Phase 2
Completed NCT01953913 - Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation Phase 3
Recruiting NCT05715229 - Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy Phase 2
Recruiting NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Phase 1/Phase 2
Suspended NCT05421936 - Osimertinib for NSCLC With Uncommon EGFR Mutations
Completed NCT02847377 - A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC N/A
Completed NCT04427072 - Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation Phase 3
Recruiting NCT04823377 - Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer. N/A